AbbVie grabs rights to biotech startup's anti-gluten drug for $70M upfront FierceBiotech AbbVie is partnered with biotech heavyweight Biogen Idec ($BIIB) on the development therapy for multiple sclerosis known as daclizumab, for instance, and the pharma company has grabbed rights to a drug from Enanta Pharmaceuticals ($ENTA) for use in ... |
